BioLine Rx Q4 Sales $194.000K Miss $651.598K Estimate

BioLine Rx (NASDAQ: BLRX) reported Q4 sales of $194,000, significantly missing the analyst consensus estimate of $651,598 by 70.23%. This represents a 98.35% decrease compared to sales of $11.749 million in the same quarter last year.